文献速递脑血管病

症状性脑海绵状血管畸形的药物治疗联合手术与单纯药物治疗比较(CARE):可行性研究与随机、开放、实用性、试点阶段试验

Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial.
PubMed 文献 · Lancet Neurol · 2024-04-18

CARE试点试验在英国和爱尔兰的神经科学中心前瞻性随机纳入72例有症状的脑海绵状血管畸形患者,1:1分配至药物治疗联合手术组或单纯药物治疗组,评估在确定性试验中解决治疗不确定性的可行性。主要临床结局为随访至少6个月内的症状性颅内出血或新发持续或进展性非出血性局灶性神经功能缺损,两组各发生2例(6%)。该试点试验超过招募目标,但确定性试验需要广泛的国际参与。

要点

  • 72例有症状脑海绵状血管畸形患者随机分配至药物治疗联合手术组(36例)或单纯药物治疗组(36例)。
  • 主要临床结局在联合手术组发生2/33例(6%;年发生率8.0%,95%CI 2.0-32.1),单纯药物组发生2/34例(6%;年发生率7.5%,95%CI 1.9-30.1)。
  • 研究者报告无死亡、无严重不良事件,发生1例方案违背和61例方案偏离。

核心结论

  • 该试点阶段试验超过了招募目标,但确定性试验将需要广泛的国际参与。

研究设计与样本

  • CARE试点试验是一项在英国和爱尔兰神经科学中心开展的前瞻性、随机、开放标签、评估者盲法、平行组试验。
  • 计划招募60例有症状脑海绵状血管畸形患者,实际随机分配72例(22%的322例合格患者),采用计算机化网络随机化按1:1分配至药物治疗联合手术组或单纯药物治疗组。
  • 随机化按神经外科医生与参与者随机化前对预期手术类型的共识进行分层,分配对研究者、参与者和照护者开放,但对临床结局事件裁定者设盲。

主要发现

  • 2021年9月27日至2023年4月28日期间,40个站点中28个(70%)参与,研究者筛查511例患者,其中322例(63%)合格,202例被接触招募,96例与其神经外科医生对是否手术存在共同不确定性。
  • 72例参与者随机分配(平均招募率每站点每月0.2例[SD 0.25]),距最近一次症状性表现的中位时间为287天(IQR 67-591)。
  • 参与者中位年龄50.6岁(IQR 38.6-59.2),68例(94%)为成人,41例(57%)为女性,66例(92%)为白人,56例(78%)有既往颅内出血,28例(39%)有既往癫痫发作。
  • 随机化前预期手术类型为神经外科切除19例(26%)、立体定向放射外科44例(61%)、无偏好9例(13%);联合手术组36例中12例分配至神经外科切除、24例分配至立体定向放射外科。
  • 3例(4%)参与者退出,1例失访,1例拒绝面对面随访,6个月临床随访时67例(93%)保留;67例中有61例(91%)遵循分配的管理策略。

关键数值与推荐

  • 主要临床结局为随访至少6个月期间由脑海绵状血管畸形或手术引起的症状性颅内出血或新发持续或进展性非出血性局灶性神经功能缺损。
  • 主要临床结局在随机分配至药物治疗联合手术组的33例中发生2例(6%;年发生率8.0%,95%CI 2.0-32.1),在随机分配至单纯药物治疗组的34例中发生2例(6%;年发生率7.5%,95%CI 1.9-30.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The highest priority uncertainty for people with symptomatic cerebral cavernous malformation is whether to have medical management and surgery or medical management alone. We conducted a pilot phase randomised controlled trial to assess the feasibility of addressing this uncertainty in a definitive trial. METHODS: The CARE pilot trial was a prospective, randomised, open-label, assessor-blinded, parallel-group trial at neuroscience centres in the UK and Ireland. We aimed to recruit 60 people of any age, sex, and ethnicity who had mental capacity, were resident in the UK or Ireland, and had a symptomatic cerebral cavernous malformation. Computerised, web-based randomisation assigned participants (1:1) to medical management and surgery (neurosurgical resection or stereotactic radiosurgery) or medical management alone, stratified by the neurosurgeon's and participant's consensus about the intended type of surgery before randomisation. Assignment was open to investigators, participants, and carers, but not clinical outcome event adjudicators. Feasibility outcomes included site engagement, recruitment, choice of surgical management, retention, adherence, data quality, clinical outcome event rate, and protocol implementation. The primary clinical outcome was symptomatic intracranial haemorrhage or new persistent or progressive non-haemorrhagic focal neurological deficit due to cerebral cavernous malformation or surgery during at least 6 months of follow-up. We analysed data from all randomly assigned participants according to assigned management. This trial is registered with ISRCTN (ISRCTN41647111) and has been completed. FINDINGS: Between Sept 27, 2021, and April 28, 2023, 28 (70%) of 40 sites took part, at which investigators screened 511 patients, of whom 322 (63%) were eligible, 202 were approached for recruitment, and 96 had collective uncertainty with their neurosurgeon about whether to have surgery for a symptomatic cerebral cavernous malformation. 72 (22%) of 322 eligible patients were randomly assigned (mean recruitment rate 0·2 [SD 0·25] participants per site per month) at a median of 287 (IQR 67-591) days since the most recent symptomatic presentation. Participants' median age was 50·6 (IQR 38·6-59·2) years, 68 (94%) of 72 participants were adults, 41 (57%) were female, 66 (92%) were White, 56 (78%) had a previous intracranial haemorrhage, and 28 (39%) had a previous epileptic seizure. The intended type of surgery before randomisation was neurosurgical resection for 19 (26%) of 72, stereotactic radiosurgery for 44 (61%), and no preference for nine (13%). Baseline clinical and imaging data were complete for all participants. 36 participants were randomly assigned to medical management and surgery (12 to neurosurgical resection and 24 to stereotactic radiosurgery) and 36 to medical management alone. Three (4%) of 72 participants withdrew, one was lost to follow-up, and one declined face-to-face follow-up, leaving 67 (93%) retained at 6-months' clinical follow-up. 61 (91%) of 67 participants with follow-up adhered to the assigned management strategy. The primary clinical outcome occurred in two (6%) of 33 participants randomly assigned to medical management and surgery (8·0%, 95% CI 2·0-32·1 per year) and in two (6%) of 34 participants randomly assigned to medical management alone (7·5%, 1·9-30·1 per year). Investigators reported no deaths, no serious adverse events, one protocol violation, and 61 protocol deviations. INTERPRETATION: This pilot phase trial exceeded its recruitment target, but a definitive trial will require extensive international engagement. FUNDING: National Institute for Health and Care Research.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial. Lancet Neurol. 2024. PMID: 38643777. doi:10.1016/S1474-4422(24)00096-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。